clinical trial · NCT03370133
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL·phase3·completed·n = 567
Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisPsoriatic ArthritisBimekizumabUstekinumabPlacebo
brief summary
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
started
Dec 6, 2017
primary completion
Jan 8, 2019
completion
Dec 13, 2019
last updated
Apr 15, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol